Prostate Cancer Diagnostics and Minimally Invasive Treatments Market | Global Markets

149 Pages | 27 Exhibits | 2019 Analysis | Forecasts Through 2023
Buy Now
Become Market Insider

Overview

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends & opportunities in the nearly $1bn Prostate Cancer Diagnostics and Minimally Invasive Treatments market.

PROSTATE CANCER DIAGNOSTICS AND MINIMALLY INVASIVE TREATMENTS MARKET HIGHLIGHTS

  • The global prostate cancer diagnostic products market was valued at nearly $270m in 2018. The market is expected to increase at a healthy rate, at more than 11% CAGR.
  • The global minimally invasive prostate cancer treatments market was valued at more than $630m in 2018. The market is expected to increase at a CAGR slightly under 10%.
  • The diagnostics market will be driven by growth in sales of advanced, precise/targeted MRI-US fusion biopsy systems and noninvasive molecular diagnostics/liquid biopsy tests capable of "ruling out" unnecessary biopsies and potentially supplementing less-than reliable PSA tests.
  • The minimally invasive treatments market will be driven by sales of robotic-assisted laparoscopic prostatectomy (RALP) instruments/accessories, ablation systems (particularly high-intensity focused ultrasound or HIFU and cryoablation), and the small but growing market of hydrogel spacers for protecting prostate tissue during radiotherapy.

 

KEY QUESTIONS ANSWERED

  • What is the value of the prostate cancer diagnostics and minimally invasive treatments market? Expected growth?
  • Estimated sales and growth by segment and region?
  • Key market drivers and limiters?
  • New products and innovations?
  • Leading competitors?
  • Estimate market share?
  • Startups or emerging competitors?
  • Trends & opportunities?

Table of Contents

Executive Summary 

i. Prostate cancer overview

ii. Prostate cancer diagnostics and minimally invasive treatments market 

a. Market drivers and limiters

b. Technology trends 

c. Market leaders

d. Competitive strategies

e. Emerging competition

iii. Methodology

iv. Bibliography

 

Exhibit ES-1: Prostate cancer diagnostic products, global market forecast 2018-23

Exhibit ES-2: Minimally invasive prostate cancer treatments, global market forecast 2018-23 

 

1. Prostate Cancer Overview

1.1 Staging 

1.2 Incidence: US, 5EU and Japan

1.3 Risk factors

1.3.1 Genetics

1.4 Detection and diagnosis

1.4.1 PSA testing 

1.4.2 Screening

1.4.3 Biopsy

1.4.4 Molecular diagnostics and liquid biopsy

1.5 Prostate Cancer Treatment pathways

1.5.1 Surgery 

1.5.2 Focal therapies

1.5.3 Chemotherapy 

1.5.4 Radiation therapy 

1.5.5 Hormonal therapy

1.5.6 Biological treatments

1.6 Bibliography

 

Exhibit 1-1: Estimated new cases of prostate cancer by stage, US, 2018 and 2023 

Exhibit 1-2: Estimated new cases of prostate cancer by stage, 5EU, 2018 and 2023

Exhibit 1-3: Estimated new cases of prostate cancer by stage, Japan, 2018 and 2023

Exhibit 1-4: Advantages and disadvantages of multiparametric MRI for prostate imaging

Exhibit 1-5: Advantages and disadvantages of liquid biopsy

Exhibit 1-6: Treatment options for prostate cancer by cancer type/stage 

Exhibit 1-7: Surgical options for prostate cancer

Exhibit 1-8: HIFU for prostate cancer using the transrectal approach

Exhibit 1-9: Advantages/disadvantages of HIFU for prostate cancer treatment 

Exhibit 1-10: Advantages/disadvantages of IRE for prostate cancer treatment 

 

2. Prostate Cancer Diagnostics

2.1 PSA tests

2.2 Molecular diagnostic and liquid biopsy products

2.3 Biopsy guidance systems 

2.3.1 Emerging biopsy products/technologies

2.4 Prostate cancer diagnostic products market

2.4.1 Global market insights

2.4.2 Market value

2.4.3 Segment insights

2.4.4 Regional insights

2.4.5 Market trends

2.4.6 Market drivers and limiters 

2.4.7 Market share

2.5 Bibliography 

 

Exhibit 2-1: Selected molecular diagnostic/liquid biopsy products for prostate cancer

Exhibit 2-2: Selected commercially available MRI-US fusion biopsy systems for prostate cancer diagnosis

Exhibit 2-3: Prostate cancer diagnostic products, combined market forecast, by product segment, 2018-23

Exhibit 2-4: Prostate cancer diagnostic products, US market forecast, 2018-2023

Exhibit 2-5: Prostate cancer diagnostic products, 5EU market forecast, 2018-2023

Exhibit 2-6: Prostate cancer diagnostic products, Japan market forecast, 2018-2023

Exhibit 2-7: Prostate cancer diagnostic products, RoW market forecast, 2018-2023 

Exhibit 2-8: 2018, Prostate cancer diagnostic products market, share by supplier 

 

3. Minimally Invasive Prostate Cancer Treatments 

3.1 Prostate cancer surgery 

3.1.1 Robotic-assisted laparoscopic prostatectomy (RALP) products

3.2 Prostate radiation therapy

3.2.1 EBRT 

3.2.2 Brachytherapy

3.2.3 Hydrogel spacers for radiotherapy 

3.3 Ablation of prostate cancer 

3.3.1 Cryoablation

3.3.2 High-intensity focused ultrasound

3.3.3 Irreversible electroporation (IRE) 

3.4 Minimally invasive prostate cancer treatments market

3.4.1 Market value

3.4.2 Segment insights

3.4.3 Regional insights

3.4.4 Market trends

3.4.5 Market drivers and limiters 

3.4.6 Market leaders

3.5 Bibliography 

3.6 Appendix 

3.6.1 Prostate cancer ablation survey

 

Exhibit 3-1: Minimally invasive prostate cancer treatments, combined market forecast, by product segment 2018-2023 

Exhibit 3-2: Minimally invasive prostate cancer treatments, US market forecast, 2018-2023 

Exhibit 3-3: Minimally invasive prostate cancer treatments, 5EU market forecast, 2018-2023 

Exhibit 3-4: Minimally invasive prostate cancer treatments, Japanese market forecast, 2018-2023 

Exhibit 3-5: Minimally invasive prostate cancer treatments, RoW market forecast, 2018-2023 

Exhibit 3-6: Minimally invasive prostate cancer treatments, forecast by region, 2018-2023 

Exhibit 3-7: 2018, Minimally invasive prostate cancer treatments, share by supplier

 

Appendix A: company listing

 

Companies Covered

Accuray

AngioDynamics

Apocell

Argon Medical Devices

Augmentix/Boston Scientific

Avateramedical

biobot Surgical

Biocept

Bio-techne

Boston Scientific

BXTAccelyon

Cell Max Life

Chronix Biomedical

CMR Surgical

Cook Medical

CR Bard

DK Technologies GmbH

Eckert & Ziegler BEBIG

EDAP TMS

Eigen

Elekta

Endocare

Epic Sciences

Exome Diagnostics

Galil Medical/BTG

Hologic

IceCure Medical

Intuitive Surgical

InVivo Corporation/Philips

IsoRay Medical

Koelis

MDxHealth

Medcom Services GmbH

Medicaroid

Meere Company

Profound Medical

Qiagen

Somatex Medical Technologies GmbH

SonaCare Medical

TransEnterix

Uromed

Varian Medical Systems